Cookson Peirce & Co. Inc. Buys New Stake in Nurix Therapeutics, Inc. $NRIX

Cookson Peirce & Co. Inc. purchased a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 23,000 shares of the company’s stock, valued at approximately $558,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Larson Financial Group LLC raised its position in shares of Nurix Therapeutics by 339.0% in the fourth quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock worth $29,000 after acquiring an additional 1,190 shares during the period. California State Teachers Retirement System increased its stake in shares of Nurix Therapeutics by 2.2% in the 4th quarter. California State Teachers Retirement System now owns 68,019 shares of the company’s stock valued at $1,290,000 after purchasing an additional 1,476 shares in the last quarter. Intesa Sanpaolo Wealth Management purchased a new position in shares of Nurix Therapeutics in the 4th quarter valued at about $31,000. Royal Bank of Canada raised its holdings in Nurix Therapeutics by 17.6% in the 4th quarter. Royal Bank of Canada now owns 10,842 shares of the company’s stock worth $206,000 after purchasing an additional 1,623 shares during the period. Finally, Arizona State Retirement System raised its holdings in Nurix Therapeutics by 8.2% in the 4th quarter. Arizona State Retirement System now owns 21,990 shares of the company’s stock worth $417,000 after purchasing an additional 1,674 shares during the period.

Nurix Therapeutics Price Performance

Shares of NRIX opened at $26.21 on Monday. Nurix Therapeutics, Inc. has a 52-week low of $8.19 and a 52-week high of $28.23. The firm’s fifty day moving average is $24.37 and its two-hundred day moving average is $19.01. The stock has a market cap of $2.72 billion, a PE ratio of -7.60 and a beta of 1.79.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings results on Thursday, July 9th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.08). The business had revenue of $9.04 million during the quarter, compared to analysts’ expectations of $15.29 million. Nurix Therapeutics had a negative return on equity of 76.09% and a negative net margin of 928.44%. As a group, research analysts anticipate that Nurix Therapeutics, Inc. will post -2.73 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on NRIX. Truist Financial raised their price objective on Nurix Therapeutics from $32.00 to $34.00 and gave the company a “buy” rating in a report on Friday, July 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $34.00 target price on shares of Nurix Therapeutics in a research note on Tuesday, August 4th. Wall Street Zen raised shares of Nurix Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Royal Bank Of Canada boosted their price target on shares of Nurix Therapeutics from $33.00 to $36.00 and gave the stock an “outperform” rating in a report on Monday, August 10th. Finally, Jefferies Financial Group increased their price objective on shares of Nurix Therapeutics from $41.00 to $45.00 and gave the company a “buy” rating in a report on Monday, June 8th. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $34.21.

Insider Activity at Nurix Therapeutics

In related news, insider Gwenn Hansen sold 4,356 shares of Nurix Therapeutics stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $25.00, for a total transaction of $108,900.00. Following the transaction, the insider owned 117,227 shares in the company, valued at approximately $2,930,675. This trade represents a 3.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Houte Hans Van sold 4,761 shares of the business’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $24.36, for a total value of $115,977.96. Following the transaction, the chief financial officer directly owned 40,166 shares in the company, valued at $978,443.76. This trade represents a 10.60% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 25,314 shares of company stock valued at $589,361. Insiders own 6.70% of the company’s stock.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.